Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases
Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. The company's pipeline includes investigational oral SYK inhibitors and a CDK9 inhibitor for treating various cancers.